CRL-40,940
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C15H13F2NO2S |
Molar mass | 309.33 g/mol |
3D model (JSmol) | |
| |
|
CRL-40,940 (also known as flmodafinil, bisfluoromodafinil and lauflumide) is a selective dopaminergic reuptake inhibitor, and is the bisfluoro analog of the wakefulness-promoting agent (or eugeroic) modafinil and has been sold online as a designer drug.[1][2][3][4] Its inventors claim that it is more effective than modafinil and adrafinil in their indications with fewer side effects, and was patented in 2013.[5] Phase I clinical trials have been underway since December 2015.[6][7]
See also
References
- ↑ Louis Lafon (28 January 1986). "Patent CA 1199916 A1 - Benzhydrylsulfinylacetamide derivatives". Retrieved 25 July 2015.
- ↑ Jianjing Cao; Thomas E. Prisinzano; Oluyomi M. Okunola; Theresa Kopajtic; Matthew Shook; Jonathan L. Katz; Amy Hauck Newman (January 2011). "SARs at the Monoamine Transporters for a Novel Series of Modafinil Analogues". ACS Medicinal Chemistry Letters. 2 (1): 48–52. PMC 3041981 . PMID 21344069. doi:10.1021/ml1002025.
- ↑ Eric Konofal (7 November 2013). "Patent US 20130295196 A1 - Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof". Retrieved 25 July 2015.
- ↑ Louis Lafon (18 December 1984). "Patent US 4489095 A - Halogenobenzhydrylsulfinylacetohydroxamic acids". Retrieved 25 July 2015.
- ↑ http://www.google.com/patents/US20130295196
- ↑ http://nlspharma.com/science/pipeline/
- ↑ http://adisinsight.springer.com/drugs/800043932
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.